Product
CPI-613 + Hydroxychloroquine
1 clinical trial
2 indications
Indication
SarcomaIndication
Clear CellClinical trial
A Phase I/II Open-Label Trial of CPI-613® (Devimistat) Plus Hydroxychloroquine to Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft TissueStatus: Completed, Estimated PCD: 2023-03-09